Latest Conference Articles

Results from phase 1 data looking at CART-ddBCMA show a 100% objective response rate among patients with relapsed/refractory multiple myeloma.

In an updated analysis of the combination of lenvatinib and pembrolizumab for patients with advanced melanoma, efficacy results continue to show a durable response.

Results from a phase 2 trial of patients with HER2-positive breast comparing TCbH alone and TCbH with pyrotinib showed significant improvement when adding pyrotinib, according to data presented at ASCO.

Utilizing a de-escalation of treatment strategy, researchers found a high response and significant results among patients with HER2+ breast cancer.

Pertuzumab, trastuzumab, and nab-paclitaxel used as neoadjuvant therapy in patients with HER2-positive locally advanced breast cancer showed comparable pathologic complete response with docetaxel, carboplatin, trastuzumab, and pertuzumab with less toxicities.

Treatment-naïve patients with melanoma who crossed over to receive pembrolizumab had an ORR of 38.8% and a 3-year PFS of 32% according to updated data from the phase 3 EORTX 1325/KEYNOTE-054 trial.

The combination of tafasitamab-cxix and lenalidomide in patients with relapsed/refractory diffuse large B-cell lymphoma showed sustainable responses at 3-year follow-up of the phase 2 L-MIND trial.

Alexander Spira, MD, PhD, FACP, director of the Virginia Cancer Specialists Research Institute, discusses the safety profile of amivantamab and lazertinib in EGFR-mutated non-small cell lung cancer, based on data from the CHRYSALIS tria.

Overall survival was maintained, and even improved, in patients with pretreated HER2-positive breast cancer receiving tucatinib plus trastuzumab and capecitabine versus placebo.

No clinical activity was elicited by selumetinib in pediatric and young adult patients with refractory cancers.

In patients with advanced or metastatic esophageal squamous cell carcinoma, Camrelizumab in combination with chemotherapy demonstrated improved overall survival and progression-free survival and a manageable safety profile as frontline therapy compared with placebo plus chemotherapy.

Overall survival in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer at almost 5 years of follow-up continued to improve with Ribociclib plus fulvestrant over fulvestrant alone, irrespective of whether patients received the regimen in the first- or second-line setting.

Encouraging clinical and pharmacodynamic activity was seen at all dose levels in patients with B-cell malignancies who received TG-1701.

Consistent efficacy was seen with selpercatinib in patients with RET fusion-positive non-small cell lung cancer, regardless of prior treatments.

Promising responses rates were seen with larotrectinib, a highly selective, central nervous system-active TRK inhibitor, in patients with TRK fusion cancer, including in those with CNS metastases at baseline.

In an update of the ARROW trial, pralsetinib was well tolerated and demonstrated robust and durable anti-tumor activity in heavily pretreated patients with multiple RET fusion–positive advanced solid tumors.

Niraparib has an acceptable safety profile for patients with platinum-sensitive recurrent ovarian cancer, regardless of the dose being adjusted for weight, according to updated results from the phase 3 NORMA trial.

Based on 7-year follow-up data, the use of front-line ibrutinib monotherapy has sustained progression-free survival and overall survival benefit compared with chlorambucil as treatment of patients with chronic lymphocytic leukemia.

The novel agent, zenocutuzumab demonstrated promise as treatment of patients with NRG1 fusion–positive cancers, in the phase 1/2 eNRGy study.

Updated results from the phase 2 CodeBreaK100 trial were presented by Ferdinandos Skoulidis, MD, PhD during the 2021 ASCO Annual Meeting.

New data from the phase 2 SPEARHEAD-1 trial showed that afami-cel can elicit encouraging responses in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

Allogeneic hematopoietic cell transplantation was shown to be safe when performed with a reduced-intensity conditioning regimen of bortezomib, fludarabine, and melphalan in patients with high-risk multiple myeloma

A robust and durable response was seen in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia after receiving a single infusion of KTE-X19, a CAR T-cell therapy.

Progression-free survival and disease control in patients with advanced synovial sarcoma was improved by catequentinib.

Early results of a phase 2 study show that the efficacy achieved with the combination of ponatinib and blinatumomab represents a potentially promising chemotherapy-free, hematopoietic stem cell transplant–sparing treatment for patients with Philadelphia chromosome–positive acute lymphocytic leukemia.

In patients with pre-immune checkpoint inhibitor-naïve advanced melanoma, treatment with the combination of lifileucel plus pembrolizumab, compared to pembrolizumab alone, increased the overall response rate.

Data from the ongoing escalation and expansion trial CTNO1552101 showed promising results for the use of TN0155 in adults with advanced solid tumors.

Amivantamab in combination with lazertinib led to responses in more than a third of patients with EGFR-mutant non–small cell lung cancer who had progressed on treatment with osimertinib but had not received chemotherapy.

Continued efficacy is seen with nivolumab and ipilimumab plus 2 cycles of versus chemotherapy alone for patients with advanced non–small cell lung cancer.

Across several previously unreported subgroups of patients with advanced urothelial cancer who have progressed on first-line platinum-containing chemotherapy avelumab as frontline maintenance plus best supportive care demonstrated a survival benefit compared with BSC alone.